Cellenkos

Cellenkos is a private, clinical-stage biotech focused on pioneering allogeneic, tissue-targeted T-regulatory cell therapies for autoimmune and inflammatory conditions. Its core technology is a proprietary platform for manufacturing cord blood-derived Tregs, licensed from MD Anderson Cancer Center, with its lead program CK0801 in clinical development. The company is backed by Golden Meditech Holdings Ltd and has established its own cGMP manufacturing facility. Cellenkos aims to address significant unmet medical needs in rare inflammatory diseases with its potentially safer, more accessible 'off-the-shelf' cell therapy approach.

Proprietary platform for manufacturing allogeneic, umbilical cord blood-derived T-regulatory (Treg) cells with naïve phenotype and potent suppressor function.

Cellenkos competes in the emerging allogeneic Treg therapy space with other biotechs like Sangamo Therapeutics (in collaboration with Sanofi) and Sonoma Biotherapeutics, as well as numerous academic centers. It also faces indirect competition from approved biologics and small molecules for autoimmune diseases and from autologous cell therapy approaches.